Sirtuins are a family of NAD+-dependent deacetylases that play crucial roles in cellular metabolism, stress response, and aging. Sirtuin signaling has emerged as an important pathway in neurodegenerative disease pathogenesis, with particular focus on SIRT1 and SIRT2 as therapeutic targets. [1]
The sirtuin family consists of seven members (SIRT1-7) in mammals, each with distinct subcellular localizations and functions. SIRT1 is primarily nuclear, SIRT2 is cytoplasmic, and SIRT3-5 are mitochondrial, while SIRT6 and SIRT7 have nuclear and nucleolar localizations respectively. [2]
These proteins require NAD+ as a cofactor, linking their activity to cellular metabolic state. This makes sirtuins crucial sensors of energy status and potential mediators of the relationship between metabolism and neurodegeneration. [3]
| Sirtuin | Subcellular Location | Primary Function | Key Substrates |
|---|---|---|---|
| SIRT1 | Nucleus | Nuclear deacetylation | p53, FOXO, PGC-1α, NF-κB |
| SIRT2 | Cytoplasm | Cytosolic deacetylation | α-tubulin, FOXO |
| SIRT3 | Mitochondria | Mitochondrial deacetylation | MnSOD, IDH2, FoxO3a |
| SIRT4 | Mitochondria | ADP-ribosyltransferase | GDH, IDE |
| SIRT5 | Mitochondria | Desuccinylase/malonylase | CPS1, GDH |
| SIRT6 | Nucleus | Chromatin deacetylation | H3K9, H3K56 |
| SIRT7 | Nucleolus | rRNA transcription | RNA Pol I, GABPβ |
SIRT1 deacetylates numerous targets relevant to neurodegeneration: [4]
SIRT1 affects amyloid precursor protein processing:
SIRT1 provides neuroprotection through:
SIRT2 is particularly implicated in PD: [8]
SIRT2 modulates α-synuclein pathology through:
SIRT3 is the primary mitochondrial deacetylase: [10]
SIRT3 provides multiple mitochondrial benefits:
SIRT6 plays critical roles in:
SIRT7 functions include:
SIRT1 deacetylates NF-κB p65, reducing:
SIRT2 modulates:
SIRT1 in senescence:
Model organism studies:
| Organism | Sirtuin | Effect | Reference |
|---|---|---|---|
| Yeast | Sir2 | Replicative lifespan extension | [17] |
| C. elegans | Sir-2.1 | Lifespan extension | [18] |
| Drosophila | dSIR2 | Lifespan extension | [19] |
| Mice | SIRT1 | Healthspan improvement | [20] |
| Compound | Pathway | Status | Clinical Trials |
|---|---|---|---|
| Nicotinamide riboside | NR → NAD+ | Clinical | AD, PD, metabolic |
| Nicotinamide mononucleotide | NMN → NAD+ | Clinical | AD, aging |
| Tryptophan | De novo pathway | Research | Limited |
| Nicotinamide | Salvage pathway | Approved | Dermatological |
NAD+ restoration provides multiple benefits: [21]
| Compound | Target | Status | Notes |
|---|---|---|---|
| Resveratrol | SIRT1 | Clinical trials | Mixed results in AD |
| SRT2104 | SIRT1 | Phase I | Safety established |
| SRT1720 | SIRT1 | Preclinical | High potency |
| Compound | Target | Disease | Status |
|---|---|---|---|
| AGK2 | SIRT2 | PD | Preclinical |
| AK-1 | SIRT2 | PD | Research stage |
| Cambinol | SIRT1/2 | Cancer | Dual inhibitor |
| Therapeutic Approach | Compound/Intervention | Target Disease | Trial Phase | Status | NCT ID |
|---|---|---|---|---|---|
| NAD+ Precursor | Nicotinamide Riboside (NR) | Alzheimer's/MCI | Phase II | Recruiting | NCT04213647 |
| NAD+ Precursor | Nicotinamide Riboside | Parkinson's Disease | Phase II | Active | NCT04434586 |
| NAD+ Precursor | Nicotinamide Mononucleotide (NMN) | Aging/MCI | Phase I/II | Completed | NCT03151269 |
| SIRT1 Activator | Resveratrol | MCI/Alzheimer's | Phase II/III | Mixed results | Various |
| SIRT1 Activator | SRT2104 | Healthy volunteers | Phase I | Completed | - |
| NAD+ Booster | NRPT (Nicotinamide Riboside + Pterostilbene) | Alzheimer's | Phase II | Recruiting | NCT05515061 |
NAD+ Metabolism Biomarkers:
Sirtuin Activity Biomarkers:
Disease State Biomarkers:
Therapeutic Potential:
Therapeutic Challenges:
Clinical Practice Integration:
Sirtuins in neurodegeneration (Nat Rev Neurosci, 2020). 2020. ↩︎
SIRT1 and Alzheimer's disease (J Alzheimers Dis, 2021). 2021. ↩︎
NAD+ metabolism in brain aging and neurodegeneration (Nat Rev Neurosci, 2020). 2020. ↩︎
SIRT1 deacetylates p53 and promotes neuronal survival (Cell, 2008). 2008. ↩︎
SIRT1 regulates tau phosphorylation and aggregation (J Neurosci, 2014). 2014. ↩︎
SIRT1 activation reduces amyloidogenic processing (Nat Cell Biol, 2009). 2009. ↩︎
PGC-1α and mitochondrial function in neurodegeneration (Nat Rev Neurosci, 2011). 2011. ↩︎
SIRT2 as a therapeutic target in Parkinson's disease (Nat Rev Neurol, 2018). 2018. ↩︎
SIRT2 inhibition prevents α-synuclein aggregation (Nat Chem Biol, 2017). 2017. ↩︎
SIRT3 deacetylates MnSOD in neurodegeneration (Cell, 2012). 2012. ↩︎
Mitochondrial SIRT3 in aging and disease (Nat Rev Endocrinol, 2019). 2019. ↩︎
SIRT6 in DNA repair and neurodegeneration (Nat Rev Neurosci, 2019). 2019. ↩︎
SIRT7 and stress response in the brain (Mol Neurodegener, 2020). 2020. ↩︎
SIRT1 deacetylates NF-κB in neuroinflammation (Nat Rev Neurosci, 2016). 2016. ↩︎
SIRT2 modulates peripheral immune infiltration (Nat Neurosci, 2019). 2019. ↩︎
Sirtuins and cellular senescence in the brain (Nat Rev Neurosci, 2018). 2018. ↩︎
C. elegans Sir-2.1 and lifespan extension (Nature, 2004). 2004. ↩︎
SIRT1 overexpression and healthspan in mice (Cell Metab, 2011). 2011. ↩︎
NAD+ supplementation in neurodegeneration (Nat Rev Neurosci, 2020). 2020. ↩︎
Clinical trials of NAD+ precursors in AD (J Prev Alzheimers Dis, 2024). 2024. ↩︎
NAD+ depletion in Alzheimer's disease brain (Nat Neurosci, 2019). 2019. ↩︎
NAD+ restoration in Parkinsons disease models (Cell, 2016). 2016. ↩︎
'Sirtuins in ALS: Pathogenic mechanisms and therapeutic targets (Nat Rev Neurol, 2020)'. 2020. ↩︎
SIRT1 activation in Huntington's disease models (Nat Med, 2013). 2013. ↩︎